ChiCTR2100051974 版本V1.8 版本创建时间2022/06/25 04:26:30 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100051974 

最近更新日期:

Date of Last Refreshed on:

2022-05-14 19:10:36 

注册时间:

Date of Registration:

2021-10-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

衰弱对老年患者椎体脆性骨折行经皮椎体强化术后转归的影响

Public title:

The effect of frailty syndrome on the outcome of percutaneous vertebral augmentation in elderly patients with vertebral fragility fractures

注册题目简写:

English Acronym:

研究课题的正式科学名称:

衰弱对老年患者椎体脆性骨折行经皮椎体强化术后转归的影响

Scientific title:

The effect of frailty syndrome on the outcome of percutaneous vertebral augmentation in elderly patients with vertebral fragility fractures

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王亚斌 

研究负责人:

王亚斌 

Applicant:

Wang Yabin 

Study leader:

Wang Yabin 

申请注册联系人电话:

Applicant telephone:

+86 13812154343

研究负责人电话:

Study leader's
telephone:

+86 13812154343

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wybsy0103@sina.com

研究负责人电子邮件:

Study leader's E-mail:

wybsy0103@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省无锡市寿山路163号

研究负责人通讯地址:

江苏省无锡市寿山路163号

Applicant address:

163 Shoushan Road, Wuxi, Jiangsu

Study leader's address:

163 Shoushan Road, Wuxi, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江阴市人民医院

Applicant's institution:

Jiangyin People's Hospital

研究负责人所在单位:

江阴市人民医院

Affiliation of the Leader:

Jiangyin People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021伦理研第037号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江阴市人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Jiangyin People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-07-29 00:00:00

伦理委员会联系人:

叶继红

Contact Name of the ethic committee:

Ye Jihong

伦理委员会联系地址:

江苏省无锡市寿山路163号

Contact Address of the ethic committee:

163 Shoushan Road, Wuxi, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江阴市人民医院

Primary sponsor:

Jiangyin People's Hospital

研究实施负责(组长)单位地址:

江苏省无锡市寿山路163号

Primary sponsor's address:

163 Shoushan Road, Wuxi, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

无锡

Country:

China

Province:

Jiangsu

City:

Wuxi

单位(医院):

江阴市人民医院

具体地址:

寿山路163号

Institution
hospital:

Jiangyin People's Hospital

Address:

163 Shoushan Road

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

骨质疏松性椎体压缩性骨折  

Target disease:

Osteoporotic vertebral compression fracture

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

主要目的:评估评估衰弱对老年骨质疏松性椎体压缩性骨折患者行椎体强化手术后早期并发症的增加、术后的疼痛缓解及功能恢复的影响。  

Objectives of Study:

Main purpose: to assess the effect of frailty on the increase of early complications, postoperative pain relief and functional recovery in elderly patients with osteoporotic vertebral compression fractures after vertebral enhancement surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.患者年龄>=65岁;
2.腰痛的视觉模拟评分(VAS)>=5分;
3.骨折水平为T5-L5;
4.入院时的骨密度测定T值<-2.5 SD;
5.MR显示新鲜骨折;
6.患者愿意接受手术治疗
7.能耐受手术的患者;
8.能完成随访的患者。

Inclusion criteria

1.The patient's age is >=65 years old;
2.Visual analogue scale (VAS) of low back pain >= 5 points;
3.The fracture level is T5-L5;
4.Determination of bone density T value <-2.5 SD;
5.The MR signal shows a fresh fracture;
6.The patient is willing to undergo surgical treatment;
7.Patients who can tolerate surgery;
8.Patients who can complete follow-up.

排除标准:

1.其他性质病理性骨折,如肿瘤、炎症等;
2.局部或全身感染的患者;
3.有神经损害症状;
4.凝血功能异常。

Exclusion criteria:

1.Other pathological fractures, such as tumors, inflammations, etc.;
2.Patients with local or systemic infections;
3.Symptoms of nerve damage;
4.Abnormal coagulation function.

研究实施时间:

Study execute time:

From 2021-08-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-01 00:00:00 To 2022-10-31 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

108

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

无锡 

Country:

China

Province:

Jiangsu

City:

Wuxi

单位(医院):

江阴市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangyin People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛视觉模拟评分

指标类型:

主要指标

Outcome:

Visual analogue pain scale

Type:

Primary indicator

测量时间点:

术前,术后1天,术后30天,术后90天

测量方法:

视觉模拟评分标尺

Measure time point of outcome:

Preoperative,1st day after operation, 30th day after operation, 90th day after operation

Measure method:

Visual analog scale scaleplate

指标中文名:

Oswestry功能障碍指数

指标类型:

主要指标

Outcome:

Oswestry disability index

Type:

Primary indicator

测量时间点:

术前,术后1天,术后30天,术后90天

测量方法:

Oswestry功能障碍指数问卷表

Measure time point of outcome:

Preoperative,1st day after operation, 30th day after operation, 90th day after operation

Measure method:

Oswestry Disability Index Questionnaire

指标中文名:

Sarc-F有关肌肉功能的简短问卷

指标类型:

主要指标

Outcome:

Sarc-F short questionnaire on muscle function

Type:

Primary indicator

测量时间点:

术前,术后30天,术后90天

测量方法:

问卷

Measure time point of outcome:

Preoperative, 30th day after operation, 90th day after operation

Measure method:

Questionnaire

指标中文名:

Frail衰弱筛查量表

指标类型:

主要指标

Outcome:

Frail Frailty Screening Scale

Type:

Primary indicator

测量时间点:

术前,术后30天,术后90天

测量方法:

问卷

Measure time point of outcome:

Preoperative, 30th day after operation, 90th day after operation

Measure method:

Questionnaire

指标中文名:

Fried衰弱表型

指标类型:

主要指标

Outcome:

Fried frailty phenotype

Type:

Primary indicator

测量时间点:

术前,术后30天,术后90天

测量方法:

问卷

Measure time point of outcome:

Preoperative, 30th day after operation, 90th day after operation

Measure method:

Questionnaire

指标中文名:

内科并发症

指标类型:

主要指标

Outcome:

Medical-related complications

Type:

Primary indicator

测量时间点:

术后90天

测量方法:

临床评估

Measure time point of outcome:

90th day after operation

Measure method:

Clinical evaluation

指标中文名:

椎体再骨折的发生

指标类型:

主要指标

Outcome:

Occurrence of re-fracture of the vertebral body

Type:

Primary indicator

测量时间点:

术后90天

测量方法:

临床评估

Measure time point of outcome:

90th day after operation

Measure method:

Clinical evaluation

指标中文名:

血常规

指标类型:

次要指标

Outcome:

blood routine examination

Type:

Secondary indicator

测量时间点:

术前

测量方法:

仪器检测

Measure time point of outcome:

Preoperative

Measure method:

Detect with instrument

指标中文名:

肝肾功能

指标类型:

次要指标

Outcome:

Liver and kidney function

Type:

Secondary indicator

测量时间点:

术前

测量方法:

仪器检测

Measure time point of outcome:

Preoperative

Measure method:

Detect with instrument

指标中文名:

骨代谢标志物

指标类型:

次要指标

Outcome:

Bone Metabolism Markers

Type:

Secondary indicator

测量时间点:

术前

测量方法:

仪器检测

Measure time point of outcome:

Preoperative

Measure method:

Detect with instrument

指标中文名:

骨密度

指标类型:

次要指标

Outcome:

Bone density

Type:

Secondary indicator

测量时间点:

术前

测量方法:

定量CT

Measure time point of outcome:

Preoperative

Measure method:

Q-CT

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

外周静脉

Sample Name:

Blood

Tissue:

Peripheral vein

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机,连续入组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-random, continuous inclusion.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文投稿时同时提供原始数据链接(文件形式:电子表格)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data link (file format: electronic form) is also provided when the paper is submitted.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集采用纸质病例报告表,并使用Excel进行数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper case report forms are used for data collection, and Excel is used for data management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-10-11 00:49:16